% | $
Quotes you view appear here for quick access.

BP p.l.c. Message Board

  • solantey Jul 18, 2010 1:43 AM Flag

    O.T. - " V V U S " - Research It Before Monday Morning

    “ V V U S “ - Vivus Inc. Substantially oversold at the current price. Due diligence.

    Company has $200,000,000 in cash on hand. Several other drugs in trials. Two year safety data on Qnexa is due out in August.

    Checkout the company’s website:

    Analyst “Buy Rating”: 7/16/2010 $12.00 Target Price:

    At around $5, Vivus shares look attractive, said JMP Securities analyst Jason Butler, who believes the game is not over for Qnexa and has a price target of $12 for Vivus. "I would be buying Vivus down here," Butler said.

    The FDA is expected to act on the Qnexa application by Oct. 28, and Butler thinks there is at least a 50 percent chance the drug will win approval within the next six months.

36.25+0.20(+0.55%)4:00 PMEDT